{
  "id": "CD015536.PUB2",
  "draft": "Is entecavir effective and safe for children and adults with chronic hepatitis B compared to no treatment or a placebo?\n\nWe looked at the benefits and harms of entecavir for children and adults with chronic hepatitis B. We wanted to know if entecavir is better than no treatment or a placebo in reducing serious health problems and improving quality of life.\n\n- We are very uncertain if entecavir reduces serious harmful effects or deaths compared to no treatment or a placebo, as the evidence we found is of very low certainty.\n- No studies reported on how entecavir affects a person's quality of life.\n- More and better research is needed, especially studies that follow people for longer.\n\nWhat is chronic hepatitis B and why is it a problem?\nChronic hepatitis B is a major public health concern worldwide. It is a liver infection caused by the hepatitis B virus (a type of virus that attacks the liver) that can lead to serious health problems, including liver damage, liver cancer, and death. Entecavir is one of the antiviral therapy options (a type of treatment that fights viruses) used to treat chronic hepatitis B.\n\nWhat did we want to find out?\nWe wanted to evaluate the benefits and harms of entecavir compared to no treatment or placebo (a dummy treatment) in children and adults with chronic hepatitis B. We aimed to find out whether entecavir is effective in reducing the risk of serious health problems, such as death from any cause and serious harmful effects, and improving quality of life.\n\nHow did we conduct this review?\nWe searched for studies comparing entecavir with no treatment or placebo in people with chronic hepatitis B, summarized their results, and rated our confidence in the evidence.\n\nWhat did we find?\nWe found 22 studies that involved 2940 people with chronic hepatitis B. The studies were conducted over a period of 5 weeks to 228 weeks. We are very uncertain if entecavir reduces serious harmful effects compared to no treatment or a placebo. It is unclear if entecavir has an effect on death from any cause. There is a lack of data on quality of life.\n\nWhat are the limitations of the evidence?\nThe limitations of the evidence are that participants may have known which treatment they received, not all studies reported all outcomes of interest, and the studies were very small.\n\nHow up-to-date is the evidence?\nThe evidence is up to date to July 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 427,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 24,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 17.791666666666668,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 9,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 36,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 28,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 17,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 119,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 56.824233508977386,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 9.753433840749413,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 8.500891881342703,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 8.796627634660421,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 14.79816549570648,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 47.53405542544887,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 5.291666666666667,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 11.54400374531753,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 7.09492568306011,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 168,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 82,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 127,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 427,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 427 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 9,
        "P50_count": 3,
        "P75_count": 6,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 50,
        "P50_percentage": 16.666666666666664,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 83.33333333333334,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a strong draft with excellent readability scores, and all critical checks for accuracy and completeness have passed. To make the summary even more helpful for patients, I recommend focusing on three areas to improve clarity and context.\n\n**1. Clarify the finding on mortality to provide full context.**\n- **Problematic Text:** In the key messages, \"We are very uncertain if entecavir reduces... deaths\". In the results, \"It is unclear if entecavir has an effect on death from any cause.\"\n- **Why it's a problem:** This phrasing might suggest to a reader that there were deaths but the data was poor. The key reason for the uncertainty is that no deaths occurred in any group, which is an important finding in itself. Providing this context is more transparent and prevents potential misinterpretation.\n- **Suggested Rewrite:** For the results section, try: \"It is unclear if entecavir has an effect on death from any cause, because no deaths were reported in either the entecavir or the placebo/no treatment groups in the studies.\"\n\n**2. Explain the impact of the evidence limitations.**\n- **Problematic Text:** \"The limitations of the evidence are that participants may have known which treatment they received, not all studies reported all outcomes of interest, and the studies were very small.\"\n- **Why it's a problem:** This lists the limitations but doesn't explain to a non-expert reader *why* these things matter. Explaining the impact helps the reader understand the reasons for the uncertainty in the findings.\n- **Suggested Rewrite:** \"Our confidence in the evidence is limited for a few reasons:\n- In some studies, participants may have known which treatment they were getting, which could have influenced the results.\n- The studies were also very small, which makes it hard to be certain about the results.\"\n\n**3. Combine and strengthen the key messages for better flow.**\n- **Problematic Text:** The three separate bullet points in the key messages section feel a bit disconnected.\n- **Why it's a problem:** The key messages are the most important part of the PLS. Combining the points can tell a more coherent story about the review's findings right from the start.\n- **Suggested Rewrite:** Consider restructuring into two stronger points: \"- Due to very low-certainty evidence, we are very uncertain whether entecavir reduces serious harmful effects compared to no treatment or a placebo. It is also unclear if it affects the risk of death.\n- The review found no information about how entecavir affects a person's quality of life, and more research is needed to understand the true benefits and harms of this treatment.\"\n",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns. An impressive 83.3% of metrics, including all readability scores (e.g., Flesch-Kincaid Grade Level of 9.75) and words per sentence (17.79), fall within the best quartile for plain language summaries. This indicates a very strong foundation in terms of readability and sentence structure. The feedback provided focuses on higher-level clarity and context rather than fixing stylistic errors."
    }
  ]
}